NO2017025I1 - Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta. - Google Patents

Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta.

Info

Publication number
NO2017025I1
NO2017025I1 NO2017025C NO2017025C NO2017025I1 NO 2017025 I1 NO2017025 I1 NO 2017025I1 NO 2017025 C NO2017025 C NO 2017025C NO 2017025 C NO2017025 C NO 2017025C NO 2017025 I1 NO2017025 I1 NO 2017025I1
Authority
NO
Norway
Prior art keywords
sialylation
alpha2
total
rfsh
follitropin
Prior art date
Application number
NO2017025C
Other languages
English (en)
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2017025(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NO2017025I1 publication Critical patent/NO2017025I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO2017025C 2008-04-16 2017-06-06 Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta. NO2017025I1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP09733497.3A EP2268666B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP14178729.1A EP2808340B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP13193214.7A EP2722339A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
NO2017025I1 true NO2017025I1 (no) 2017-06-06

Family

ID=39717519

Family Applications (2)

Application Number Title Priority Date Filing Date
NO2017025C NO2017025I1 (no) 2008-04-16 2017-06-06 Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta.
NO2017050C NO2017050I1 (no) 2008-04-25 2017-09-28 Rekombinant FSH (folikkel-stimulerende hormon)

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2017050C NO2017050I1 (no) 2008-04-25 2017-09-28 Rekombinant FSH (folikkel-stimulerende hormon)

Country Status (29)

Country Link
US (5) US8951967B2 (no)
EP (7) EP3045471B1 (no)
JP (7) JP2011519359A (no)
KR (5) KR20180095140A (no)
CN (3) CN102066414A (no)
AR (1) AR071479A1 (no)
AU (5) AU2009237479B2 (no)
BR (1) BRPI0910461B8 (no)
CA (1) CA2725257A1 (no)
CY (1) CY1115413T1 (no)
DK (4) DK3144318T3 (no)
ES (3) ES2610277T3 (no)
FR (1) FR17C1020I2 (no)
HK (2) HK1146284A1 (no)
HR (3) HRP20140535T1 (no)
HU (5) HUE030652T4 (no)
IL (2) IL208538A (no)
LT (4) LT3045471T (no)
MX (3) MX2010011343A (no)
NO (2) NO2017025I1 (no)
NZ (1) NZ588381A (no)
PL (4) PL2268666T3 (no)
PT (4) PT2808340T (no)
RU (3) RU2537268C2 (no)
SA (1) SA109300228B1 (no)
SI (4) SI3045471T1 (no)
TW (1) TWI488640B (no)
WO (1) WO2009127826A1 (no)
ZA (1) ZA201007373B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
ES2547233T5 (es) 2010-09-29 2024-03-27 Ferring Bv Composición para su uso en el tratamiento de la esterilidad
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AU2012340501A1 (en) * 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
WO2013161958A1 (ja) * 2012-04-27 2013-10-31 日本ケミカルリサーチ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
DK3662925T3 (da) 2015-04-17 2021-06-28 Ferring Bv Sammensætning, der omfatter fsh, til behandling af infertilitet
RU2719468C2 (ru) 2015-06-26 2020-04-17 Ферринг Б.В. Способы очистки и/или вирусной инактивации
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
MX2020002235A (es) 2017-09-01 2020-07-20 Ferring Bv Composicion para la estimulacion ovarica controlada.
TW201945024A (zh) 2018-04-30 2019-12-01 荷蘭商菲林公司 用於經控制之卵巢刺激的組成物
TW202027780A (zh) 2018-10-17 2020-08-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
WO2023186331A1 (en) 2022-04-01 2023-10-05 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
WO2024008971A1 (en) 2022-07-08 2024-01-11 Ferring B.V. Compositions and methods for intrauterine insemination (iui)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
KR100449181B1 (ko) 1995-06-15 2005-01-24 크루셀 홀란드 비.브이. 유전자요법에사용할수있는사람의재조합아데노바이러스패키징시스템
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
EP1176976B2 (en) 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
MEP38608A (en) * 2001-10-22 2011-02-10 Merck Serono Sa Gonadotrophins for folliculogenesis
EA012340B1 (ru) 2001-10-29 2009-10-30 Круселл Холланд Б.В. Способ получения гликозилированной белковой молекулы, содержащей структуру lewis x, и/или сиалил-lewis x, и/или lacdinac
NZ533124A (en) 2001-12-07 2005-11-25 Crucell Holland B Production of viruses, viral isolates and vaccines
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
US8431355B2 (en) 2004-02-04 2013-04-30 Universite De Provence Aix-Marseille 1 Process for screening glycoform-specific antibodies
CA2557725C (en) 2004-02-13 2015-06-30 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016575A1 (en) 2010-08-03 2012-02-09 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
ES2547233T5 (es) 2010-09-29 2024-03-27 Ferring Bv Composición para su uso en el tratamiento de la esterilidad
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
US20170035854A1 (en) 2014-04-18 2017-02-09 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
SI3045471T1 (sl) 2017-07-31
EP3144318B1 (en) 2020-09-23
US9546204B2 (en) 2017-01-17
US20150065695A1 (en) 2015-03-05
HUS1700024I1 (hu) 2017-06-28
US20110105398A1 (en) 2011-05-05
JP6486310B2 (ja) 2019-03-20
AU2017204259B2 (en) 2017-08-17
PL2808340T3 (pl) 2017-02-28
US20180079794A1 (en) 2018-03-22
FR17C1020I2 (fr) 2020-04-10
HK1199039A1 (en) 2015-06-19
PT3045471T (pt) 2017-06-14
EP2808340A1 (en) 2014-12-03
EP4015527A1 (en) 2022-06-22
HRP20161520T1 (hr) 2016-12-30
IL208538A (en) 2014-03-31
NZ588381A (en) 2012-05-25
LT2808340T (lt) 2016-11-10
US9771407B2 (en) 2017-09-26
RU2537268C2 (ru) 2014-12-27
EP2808340B1 (en) 2016-08-17
IL230571A (en) 2015-11-30
US10995128B2 (en) 2021-05-04
WO2009127826A1 (en) 2009-10-22
US20210332099A1 (en) 2021-10-28
TW200948378A (en) 2009-12-01
BRPI0910461B1 (pt) 2021-02-23
KR20160056960A (ko) 2016-05-20
SI2808340T1 (sl) 2016-12-30
JP2018021037A (ja) 2018-02-08
US11952407B2 (en) 2024-04-09
AU2017225020A1 (en) 2017-09-28
KR20190092608A (ko) 2019-08-07
ZA201007373B (en) 2011-06-29
PT2268666E (pt) 2014-06-25
DK3045471T3 (en) 2017-06-26
AU2017204258A1 (en) 2017-07-20
RU2014141994A (ru) 2016-05-10
ES2629392T3 (es) 2017-08-09
AU2017225020B2 (en) 2019-11-14
TWI488640B (zh) 2015-06-21
KR20170110741A (ko) 2017-10-11
EP2722339A1 (en) 2014-04-23
RU2745557C3 (ru) 2021-12-10
PT2808340T (pt) 2016-11-21
JP7316905B2 (ja) 2023-07-28
HUE030652T4 (en) 2017-09-28
DK2268666T3 (da) 2014-05-12
PT3144318T (pt) 2020-11-04
CA2725257A1 (en) 2009-10-22
SI2268666T1 (sl) 2014-07-31
JP2020040956A (ja) 2020-03-19
JP2015120696A (ja) 2015-07-02
JP6762916B2 (ja) 2020-09-30
AU2009237479A1 (en) 2009-10-22
RU2014141994A3 (no) 2018-05-28
LTPA2017018I1 (lt) 2017-06-26
MX355457B (es) 2018-04-19
EP2268666B1 (en) 2014-03-12
EP3098234A1 (en) 2016-11-30
EP3045471A1 (en) 2016-07-20
JP2024038000A (ja) 2024-03-19
CY1115413T1 (el) 2017-01-04
AU2014203277A1 (en) 2014-07-24
RU2745557C1 (ru) 2021-03-29
PL2268666T3 (pl) 2014-08-29
JP2017060476A (ja) 2017-03-30
ES2468318T3 (es) 2014-06-16
JP2022031652A (ja) 2022-02-22
HRP20170958T1 (hr) 2017-09-22
RU2682270C2 (ru) 2019-03-18
AU2014203277B2 (en) 2017-04-06
SA109300228B1 (ar) 2014-04-08
LT3045471T (lt) 2017-07-10
MX348622B (es) 2017-06-22
NO2017050I1 (no) 2017-09-28
HK1146284A1 (en) 2011-05-20
EP3045471B1 (en) 2017-03-29
HUE030652T2 (en) 2017-05-29
CN105906702A (zh) 2016-08-31
EP3144318A1 (en) 2017-03-22
KR20110005863A (ko) 2011-01-19
LTPA2017029I1 (lt) 2017-10-10
SI3144318T1 (sl) 2020-12-31
US20160347811A1 (en) 2016-12-01
KR102108377B1 (ko) 2020-05-08
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
KR101622944B1 (ko) 2016-05-23
PL3045471T3 (pl) 2017-10-31
BRPI0910461A2 (pt) 2018-03-27
AU2014203277C1 (en) 2017-07-27
AU2009237479B2 (en) 2014-05-15
AR071479A1 (es) 2010-06-23
AU2017204258B2 (en) 2017-08-17
RU2010141908A (ru) 2012-05-27
DK2808340T3 (en) 2016-12-05
US8951967B2 (en) 2015-02-10
MX2010011343A (es) 2011-01-20
JP2011519359A (ja) 2011-07-07
PL3144318T3 (pl) 2021-02-08
CN105906703A (zh) 2016-08-31
EP2268666A1 (en) 2011-01-05
AU2017204259A1 (en) 2017-07-20
HUS1700036I1 (hu) 2017-10-30
IL208538A0 (en) 2010-12-30
CN102066414A (zh) 2011-05-18
FR17C1020I1 (no) 2020-04-10
HUE033830T2 (en) 2018-01-29
DK3144318T3 (da) 2020-12-07
BRPI0910461B8 (pt) 2021-05-25
HUS1700025I1 (hu) 2017-06-28
BRPI0910461A8 (pt) 2018-10-16
KR20180095140A (ko) 2018-08-24

Similar Documents

Publication Publication Date Title
NO2017025I1 (no) Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta.
WO2007106690A3 (en) Degenerate nucleobase analogs
WO2017070626A3 (en) Respiratory virus vaccines
WO2018031818A3 (en) Substituted nucleosides, nucleotides and analogs thereof
MX2021001573A (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos.
CN106573011A8 (zh) 取代的核苷、核苷酸和其类似物
WO2010101663A3 (en) Live attenuated influenza virus vaccines comprising microrna response elements
JP2011527560A5 (no)
BRPI0920026A2 (pt) método de tratamento de infecção pulmonar, composição farmacêutica e respectivos usos.
PH12015502588A1 (en) 4`-fluoro-2`-methyl substituted nucleoside derivatives
WO2011139699A3 (en) 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2007109600A3 (en) Extractions and methods comprising elder species
MX2010001849A (es) Depsipeptidos ciclicos.
MX2020011677A (es) Proceso para preparar esteres de acido lactico y acido 2-hidroxi-3-butenoico o analogos de alfa-hidroxi-metionina a partir de azucares.
Kosho et al. A response to: loss of dermatan-4-sulfotransferase 1 (D4ST1/CHST14) function represents the first dermatan sulfate biosynthesis defect," dermatan sulfate-deficient Adducted Thumb-Clubfoot Syndrome". Which name is appropriate," Adducted Thumb-Clubfoot Syndrome" or" Ehlers-Danlos syndrome"?
NO20090958L (no) Behandling av revmatismesykdom med langsom frigivelse av glukokortikoid
DK2247573T3 (da) Kulsyre- og svovlsyresalte af 3-(2,2,2-trimethylhydrazinium)propionatstere af anvendelse deraf til fremstilling og 3-(2,2,2-trimethylhydrazinium)propionat-dihydrat
WO2008133759A3 (en) Antiviral peptides
MX2009011176A (es) Extractos secos de pelargonium sidoides y pelargonium reniforme.
WO2014039330A8 (en) Transcriptional gene silencing of endogenes in plants
EP2192183A4 (en) TRITERPENE OXIDASE DERIVED FROM A PLANT BELONGING TO THE GENUS <I> GLYCYRRHIZA </ I>, GENE ENCODING TRITERPENE OXIDASE, AND USE OF THE PROTEIN OR GENE
WO2010136841A3 (en) Meganuclease variants cleaving the genome of a non-genomically integrating virus and uses thereof
JP2009196854A5 (no)
WO2015162172A3 (en) Incrnas for therapy and diagnosis of angiogenesis
TH170162A (th) ตัวเร่งปฏิกิริยาควบคุมแก๊สไอเสีย